Disease · MONDO_0001020
amblyopia
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. amblyopia. Diseases, record MONDO_0001020. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001020
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs9
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ATROPINE | CHEMBL517712 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| LEVODOPA | CHEMBL1009 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| CARBIDOPA | CHEMBL1200748 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ECHOTHIOPHATE IODIDE | CHEMBL1200367 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CAFFEINE | CHEMBL113 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DOCONEXENT | CHEMBL367149 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| VALPROIC ACID | CHEMBL109 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DONEPEZIL | CHEMBL502 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FLUOXETINE | CHEMBL41 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets12
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ACHE | Acetylcholinesterase | 2 | Acetylcholinesterase inhibitor | Phase 2 | https://conductscience.org/library/genes/43 | Drugs and targets |
| ADORA1 | Adenosine receptor | 1 | Adenosine receptor antagonist | Phase 1/2 | https://conductscience.org/library/genes/134 | Drugs and targets |
| ADORA2A | Adenosine receptor | 1 | Adenosine receptor antagonist | Phase 1/2 | https://conductscience.org/library/genes/135 | Drugs and targets |
| ADORA2B | Adenosine receptor | 1 | Adenosine receptor antagonist | Phase 1/2 | https://conductscience.org/library/genes/136 | Drugs and targets |
| ADORA3 | Adenosine receptor | 1 | Adenosine receptor antagonist | Phase 1/2 | https://conductscience.org/library/genes/140 | Drugs and targets |
| ALDH5A1 | Succinate-semialdehyde dehydrogenase, mitochondrial | 1 | Succinate semialdehyde dehydrogenase inhibitor | Phase 1/2 | https://conductscience.org/library/genes/7915 | Drugs and targets |
| CHRM1 | Muscarinic acetylcholine receptor M1 | 1 | Muscarinic acetylcholine receptor M1 antagonist | Phase 3 | https://conductscience.org/library/genes/1128 | Drugs and targets |
| CHRM2 | Muscarinic acetylcholine receptor M2 | 1 | Muscarinic acetylcholine receptor M2 antagonist | Phase 3 | https://conductscience.org/library/genes/1129 | Drugs and targets |
| CHRM3 | Muscarinic acetylcholine receptor M3 | 1 | Muscarinic acetylcholine receptor M3 antagonist | Phase 3 | https://conductscience.org/library/genes/1131 | Drugs and targets |
| DDC | Aromatic-L-amino-acid decarboxylase | 1 | DOPA decarboxylase inhibitor | Phase 3 | https://conductscience.org/library/genes/1644 | Drugs and targets |
1 to 10 of 12
See all 12 targetsTrials15
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00315302 | Trial Comparing Atropine to Atropine Plus a Plano Lens for the Sound Eye for Amblyopia in Children 3 to <7 Years Old | Phase 3 | 240 | 2011-08-11 | Amblyopia | ATROPINE | Its record names the disease | ClinicalTrials.gov |
| NCT00315328 | Trial Comparing Patching Versus Atropine for Amblyopia in 7 to < 13 Year Olds | Phase 3 | 233 | 2011-06-06 | Amblyopia | ATROPINE | Its record names the disease | ClinicalTrials.gov |
| NCT01190813 | Levodopa for the Treatment of Residual Amblyopia | Phase 3 | 139 | 2015-02-13 | Amblyopia | CARBIDOPA, LEVODOPA | Its record names the disease | ClinicalTrials.gov |
| NCT00944710 | Augmenting Atropine Treatment for Amblyopia in Children 3 to < 8 Years Old | Phase 3 | 73 | 2014-10-24 | Amblyopia | ATROPINE | Its record names the disease | ClinicalTrials.gov |
| NCT00506675 | Combined Patching-Atropine for Residual Amblyopia | Phase 3 | 55 | 2011-03-23 | Amblyopia | ATROPINE | Its record names the disease | ClinicalTrials.gov |
| NCT00789672 | Pilot Study to Evaluate Levodopa as Treatment for Residual Amblyopia | Phase 2 | 33 | 2011-03-23 | Amblyopia | LEVODOPA | Its record names the disease | ClinicalTrials.gov |
| NCT00094692 | An Evaluation of Treatment of Amblyopia in Children 7 To <18 Years Old | Phase 3 | 507 | Amblyopia | ATROPINE | Its record names the disease | ClinicalTrials.gov | |
| NCT00000170 | Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia | Phase 3 | 419 | Amblyopia | ATROPINE | Its record names the disease | ClinicalTrials.gov | |
| NCT07417046 | Possible Beneficial Effects Of Combined Fluoxetine And Occlusion Therapy In Improving And Maintaining Vision In Amblyopia Using Optical Coherence Tomography Angiography (OCTA) And Visual Evoked Potential (VEP). The Aim Of The Study Is To Evaluate Possible Beneficial Effects For Different Age Groups. | Not applicable | 50 | Amblyopia, VEP | FLUOXETINE | Its record names the disease | ClinicalTrials.gov | |
| NCT07226141 | Valproate for the Treatment of Residual Amblyopia | Phase 1/2 | 28 | Amblyopia, Amblyopia Unilateral, Amblyopia, Anisometropic, Amblyopia Strabismic | VALPROIC ACID | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 15
See all 15 trialsComparisons in its trials8
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Levodopa/Carbidopa vs Placebo: serious adverse events | 0 of 90 | 0 of 49 | 139 | NCT01190813 | Trial comparisons |
| Levodopa/Carbidopa vs Placebo: Amblyopic Eye Visual Acuity Improvement Treatment Group Comparison at 18 Weeks | 13 of 86 | 2 of 45 | 131 | NCT01190813 | Trial comparisons |
| Intensified Treatment vs Control: serious adverse events | 0 of 33 | 0 of 40 | 73 | NCT00944710 | Trial comparisons |
| Intensified Treatment vs Control: Treatment Group Comparison of the Proportion of Participants Who Achieved 20/25 or Better Visual Acuity at 10 Weeks Since Randomization | 6 of 33 | 4 of 39 | 72 | NCT00944710 | Trial comparisons |
| Intensified Treatment vs Control: Treatment Group Comparison of the Proportion of Participants Who Have Improved by 2 or More logMAR Visual Acuity Lines at 10 Weeks Since Randomization | 9 of 33 | 8 of 39 | 72 | NCT00944710 | Trial comparisons |
| Intensified Treatment vs Control: Treatment Group Comparison of the Proportion of Participants Who Have Improved by 2 or More logMAR Visual Acuity Lines Based on Visual Acuity at Best Outcome Visit | 20 of 33 | 11 of 39 | 72 | NCT00944710 | Trial comparisons |
| Intensive vs Weaning: serious adverse events | 0 of 27 | 0 of 28 | 55 | NCT00506675 | Trial comparisons |
| Lower Dose 0.51 mg Levodopa/Carbidopa vs Higher Dose 0.76 mg Levodopa/Carbidopa: serious adverse events | 0 of 16 | 0 of 17 | 33 | NCT00789672 | Trial comparisons |
Papers from its trials19
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001020
GET https://conductscience.org/api/diseases/v1/MONDO_0001020/drugs